UCLA professor receives grant to study immunotherapy for brain tumors

Photo of Robert Prins
Robert M. Prins

Robert M. Prins, PhD, received a $750,000 grant from Brain Tumor Funders’ Collaborative to support his research of immunotherapies for brain tumors.

Prins is professor of neurosurgery and molecular and medical pharmacology at David Geffen School of Medicine at UCLA, immunologist at UCLA Jonsson Comprehensive Cancer Center, and researcher with Parker Institute for Cancer Immunotherapy Center at UCLA.

Limited advances have been made in the past 20 years for treatment of malignant gliomas, an aggressive form of brain cancer.

Prins and his colleagues from UCLA Brain Tumor Center are studying immune-based therapies in hopes of identifying new, effective treatment strategies.

They now are studying whether checkpoint blockade in conjunction with a personalized dendritic cell vaccine will benefit patients with glioblastoma, a form of malignant glioma previously thought to be shielded from the immune system.

The Brain Tumor Funders’ Collaborative is a partnership between six private philanthropic and advocacy organizations dedicated to accelerating progress in brain tumor research by supporting research and collaborations.

Photo of Robert Prins
Robert M. Prins

Robert M. Prins, PhD, received a $750,000 grant from Brain Tumor Funders’ Collaborative to support his research of immunotherapies for brain tumors.

Prins is professor of neurosurgery and molecular and medical pharmacology at David Geffen School of Medicine at UCLA, immunologist at UCLA Jonsson Comprehensive Cancer Center, and researcher with Parker Institute for Cancer Immunotherapy Center at UCLA.

Limited advances have been made in the past 20 years for treatment of malignant gliomas, an aggressive form of brain cancer.

Prins and his colleagues from UCLA Brain Tumor Center are studying immune-based therapies in hopes of identifying new, effective treatment strategies.

They now are studying whether checkpoint blockade in conjunction with a personalized dendritic cell vaccine will benefit patients with glioblastoma, a form of malignant glioma previously thought to be shielded from the immune system.

The Brain Tumor Funders’ Collaborative is a partnership between six private philanthropic and advocacy organizations dedicated to accelerating progress in brain tumor research by supporting research and collaborations.

    See more from Immuno-Oncology Resource Center